JP2022529845A - スフィンゴシン１リン酸受容体調節因子 - Google Patents

スフィンゴシン１リン酸受容体調節因子 Download PDF

Info

Publication number
JP2022529845A
JP2022529845A JP2021563237A JP2021563237A JP2022529845A JP 2022529845 A JP2022529845 A JP 2022529845A JP 2021563237 A JP2021563237 A JP 2021563237A JP 2021563237 A JP2021563237 A JP 2021563237A JP 2022529845 A JP2022529845 A JP 2022529845A
Authority
JP
Japan
Prior art keywords
compound
acid
pharmaceutically acceptable
salt
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529845A5 (https=
Inventor
ターンブル，フィリップ
マーティンボロー，エスター
マルシーニ，モーリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptos LLC
Original Assignee
Receptos LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptos LLC filed Critical Receptos LLC
Publication of JP2022529845A publication Critical patent/JP2022529845A/ja
Publication of JP2022529845A5 publication Critical patent/JP2022529845A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021563237A 2019-04-26 2020-03-27 スフィンゴシン１リン酸受容体調節因子 Pending JP2022529845A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839495P 2019-04-26 2019-04-26
US62/839,495 2019-04-26
PCT/US2020/025142 WO2020219207A1 (en) 2019-04-26 2020-03-27 Sphingosine 1 phosphate receptor modulator

Publications (2)

Publication Number Publication Date
JP2022529845A true JP2022529845A (ja) 2022-06-24
JP2022529845A5 JP2022529845A5 (https=) 2023-03-30

Family

ID=72941745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563237A Pending JP2022529845A (ja) 2019-04-26 2020-03-27 スフィンゴシン１リン酸受容体調節因子

Country Status (6)

Country Link
US (1) US20220227722A1 (https=)
EP (1) EP3959204A4 (https=)
JP (1) JP2022529845A (https=)
KR (1) KR20220007065A (https=)
CN (1) CN114008034A (https=)
WO (1) WO2020219207A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503134A (ja) * 2019-11-22 2023-01-26 ビーエーエスエフ コーティングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 腐食防止剤としてカテコール誘導体を含有する電着塗装材料

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510885A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
US20180016244A1 (en) * 2015-04-06 2018-01-18 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
WO2018208855A1 (en) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
US20180369212A1 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782991A1 (en) * 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510885A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
US20180016244A1 (en) * 2015-04-06 2018-01-18 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
WO2018208855A1 (en) * 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
US20180369212A1 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503134A (ja) * 2019-11-22 2023-01-26 ビーエーエスエフ コーティングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 腐食防止剤としてカテコール誘導体を含有する電着塗装材料

Also Published As

Publication number Publication date
CN114008034A (zh) 2022-02-01
EP3959204A4 (en) 2022-12-28
EP3959204A1 (en) 2022-03-02
US20220227722A1 (en) 2022-07-21
WO2020219207A1 (en) 2020-10-29
KR20220007065A (ko) 2022-01-18

Similar Documents

Publication Publication Date Title
WO2021238817A1 (zh) 大环jak抑制剂及其应用
JP2021091736A (ja) Ａｃｃ阻害剤およびその固体形態を調製するためのプロセス
JP7089141B2 (ja) 新規なｊａｋ１選択的阻害剤およびその使用
EP4332102A1 (en) Isoquinolone compound and use thereof
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
TWI760419B (zh) 作為酪胺酸蛋白激酶抑制劑之新穎的胺基-咪唑并吡啶衍生物及其醫藥用途
JP7660102B2 (ja) Ｎヘテロ五員環含有カプシドタンパク質集合阻害剤の結晶形及びその使用
RU2704251C2 (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
JP7659343B6 (ja) ピロロピリミジン系化合物の塩、その結晶及びその使用
US20130158053A1 (en) Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
EP4403174A2 (en) Pyrrolo[1,2-b]pyridazine derivatives
EP4006031A1 (en) Dihydro-pyrrolo-pyrimidine selective jak2 inhibitor
WO2019057112A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
JP2022529845A (ja) スフィンゴシン１リン酸受容体調節因子
WO2020151746A1 (zh) 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
WO2024012425A1 (zh) 作为ripk1抑制剂的杂环化合物
CN115427397B (zh) 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用
WO2019228330A1 (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
JP5077232B2 (ja) ベンゾオキサジアゾール誘導体の結晶
KR20250112264A (ko) 퀴놀린아민계 화합물의 결정형 및 이의 제조 방법
AU2022341114A1 (en) Thienopyrrole compounds
CN118251381A (zh) 作为hmrgx1受体的增强剂的氘代(三氟甲基)嘧啶-2-胺化合物
TW202100513A (zh) 氘原子取代的吲哚甲酰胺類衍生物的晶型及其製備方法
WO2024149150A1 (zh) 氘代吡唑并嘧啶衍生物及其制备方法和药物组合物、结合物及应用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240827